Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies
IMT-009 Phase 1/2a clinical trial initiation expected in Q4 2022
Preclinical data indicate that IMT-009 restores tumor killing activity with potential for use as monotherapy or in combination with existing therapeutics
WALTHAM, Mass., Sept. 21, 2022 ... Biopharmaceuticals, Oncology, FDA Immunitas Therapeutics, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news